What Alchem Laboratories does

Alchem Laboratories Corporation is a privately held contract research organization founded in 1997 and headquartered in Alachua, Florida (a wholly owned subsidiary of TRON Group Inc.). It operates four co-located facilities providing end-to-end pharmaceutical development services spanning custom organic synthesis, ultra high-throughput screening, cGMP manufacturing of active pharmaceutical ingredients and finished drug products in topical, oral, and injectable forms, analytical method development, and clinical trial materials production. The company reports supporting APIs and drug products for more than 80 clinical trials over the last ten years, with 22 studies currently active on clinicaltrials.gov, and claims access to approximately 805,000 small-molecule compounds (385,000 NIH MLPCN plus 420,000 synthetic) for screening through its Discovery Cure Institute affiliate.

Name

Alchem Laboratories

Legal name

Alchem Laboratories Corporation

Website

https://alchem.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Alchem Laboratories is a privately held Alachua, FL-based contract research organization providing custom organic synthesis, cGMP API and drug-product manufacturing, analytical services, and uHTS screening for NIH, DOD, and pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research and Manufacturing (CRO)

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Contract research organization
• Custom organic synthesis
• CGMP API manufacturing
• Pharmaceutical drug development
• Analytical chemistry services

Headquarters

HQ city

Alachua

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Government contracts: IDIQ (Indefinite Delivery Indefinite Quantity) contracts with NIH institutes (NCATS-NIDA, NCI, NIAID, NINDS), DOD, and BARDA for drug development, synthesis, and manufacturing services. Revenue is earned through task orders placed against established contract ceilings.
2. Contract research organization (CRO) services: Custom synthesis and drug development services for pharmaceutical companies (established and start-ups). Services include FTE-based (Full-Time Equivalent) service engagements for months to years, as well as fixed-price cGMP manufacturing projects for lead compounds in up to kilogram quantities.
3. Strategic partnerships and collaborations: Revenue-generating partnerships including the Mark Cuban Cost Plus Drugs alliance for essential medicines manufacturing and North American onshoring initiatives with Applied Pharmaceutical Innovation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Alchem Laboratories is a contract research organization that provides end-to-end pharmaceutical development services including custom organic synthesis of novel compounds, cGMP manufacturing of APIs and drug products in topical, oral, and injectable forms, preclinical drug discovery (uHTS and lead optimization), analytical method development and validation, and clinical trial materials manufacturing. Services are delivered to government agencies (NIH, DOD, BARDA) under IDIQ contracts and to established and start-up pharmaceutical companies via FTE-based and fixed-price engagements.

Product overview

Alchem Laboratories Corporation is a contract research organization (CRO) founded in 1997 that provides end-to-end pharmaceutical development services. The company operates a platform-plus-services model offering Custom Synthesis Services for novel compound design and scale-up, paired with cGMP Manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products in topical, oral, and injectable forms. Discovery Cure Institute (Alchem-DCI) provides preclinical drug discovery capabilities including ultra high-throughput screening and ADMET studies. Analytical Services support method development, validation, and quality control release testing. Clinical Trial Materials services enable CTM manufacturing for clinical studies. The company holds government contracts with NIH, DOD, and BARDA, and has established partnerships with major pharmaceutical companies and research institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Synthesis Services Custom synthesis of novel compounds, new synthetic routes for known compounds, scale-up from gram to kilogram quantities, and chemical process development for pharmaceutical companies.
• Active Pharmaceutical Ingredients (APIs) cGMP manufacturing of essential medicines and APIs including Albuterol Sulfate, Amikacin Sulfate, Atropine Sulfate, Carboplatin, Ciprofloxacin, Cisplatin, Diltiazem Hydrochloride, Dobutamine Hydrochloride, Dopamine Hydrochloride, Fluconazole, Levofloxacin, Lidocaine Hydrochloride, Linezolid, Meropenem, Metronidazole, and others at gram to kilogram scale.
• Discovery Cure Institute (Alchem-DCI) Preclinical drug discovery services including assay development, ultra high-throughput screening (uHTS), hit-to-lead and lead optimization chemistry, early pharmacology, and ADMET studies, with access to NIH Molecular Libraries compounds (~385,000) and approximately 420,000 synthetic small-molecule compounds.
• cGMP Manufacturing cGMP manufacturing of APIs and drug products in topical, oral, and injectable formulations for preclinical and clinical studies, with batch sizes from several grams to several kilograms.
• Analytical Services Analytical method development, validation, transfer, process monitoring, impurity assays, reference standard validation, product characterization, stability studies, QC release testing, and environmental monitoring using NMR, HPLC, GC, MS, and other techniques.
• Clinical Trial Materials CMC documentation, formulation development, and manufacturing of clinical trial materials (CTM) for Phase I-III clinical studies, supporting over 80 clinical trials including 22 active clinical studies listed on clinicaltrials.gov.

Quantifiable outcome

• Over 80 clinical trials supported with API and drug product manufacturing in the last 10 years
• +4 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

33 partnerships are on record, tiered flagship, core and minor.

• Mark Cuban Cost Plus DrugsflagshipStrategic or Co-development Partner · 27 January 2026Strategic alliance to develop essential medicine therapeutics and improve supply chain resiliency through automated manufacturing using AI and machine learning. Initially focusing on lidocaine and diltiazem production. Collaboration will supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials.
• Applied Pharmaceutical Innovation (API-Canada)coreStrategic or Co-development Partner · 1 September 2025North American onshoring of critical therapies through collaboration for essential medicines supply chain resiliency. Expands upon previous September 2025 agreement for domestic manufacturing of critical drugs.
• National Cancer Institute (NCI) / NIHcoreStrategic or Co-development PartnerNCI's main contractor for non-GMP and GMP API synthesis projects supporting NCI clinical trials. Multiple active IDIQ contracts including 'Synthesis of Non-GMP Small Molecules' (5-year IDIQ) and 'Analysis and Synthesis of GMP and non-GMP Bulk Drugs and Pharmaceutical Formulations'.
• NCATS-NIDAcoreStrategic or Co-development PartnerGovernment contracting partner for Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products (7-year IDIQ contract 75N95024D00035, 8/1/24-7/31/31) and CRO Support for NCATS Medicinal Chemistry for Lead Optimization.
• NIAID-NIHcoreStrategic or Co-development PartnerGovernment contracting partner for Interventional Agents Chemistry Services (IACS) - 7-year IDIQ contract (75N93025D00007, 9/15/25 to 9/14/32) and Preclinical Services for HIV Therapeutics (7-year contract).
• NINDS-NIHcoreStrategic or Co-development PartnerGovernment contracting partner for Drug Manufacturing and Formulation Program (DMFP) - 10-year IDIQ contract (75N98026D00012, 5/4/26-5/3/36).
• U.S. Army Medical Research Acquisition Activity (USAMRAA) / Department of Defense (DoD)coreStrategic or Co-development PartnerLong-standing government partner for medical research and development with DoD.
• National Institute of Standards and Technology (NIST)minorStrategic or Co-development PartnerCollaboration with NIST for standards and measurement support in pharmaceutical development.
• U.S. Department of Agriculture (USDA)minorStrategic or Co-development PartnerGovernment partnership for agricultural and pharmaceutical research applications.
• Medical CBRN Defense Consortium (MCDC)coreStrategic or Co-development PartnerActive participation in Medical CBRN (Chemical, Biological, Radiological, and Nuclear) Defense Consortium for development of medical countermeasures.
• Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (ICP)minorStrategic or Co-development PartnerInternational academic collaboration for clinical pharmacology research.
• Atossa Genetics Inc. (NASDAQ: ATOS)minorStrategic or Co-development PartnerPharmaceutical company collaboration.
• Andarix Pharmaceuticals, Inc.minorStrategic or Co-development PartnerPharmaceutical company collaboration.
• BeeCured BiotechminorStrategic or Co-development PartnerBiotechnology company partnership.
• Bio Protectant Technologies Inc.minorStrategic or Co-development PartnerBiotechnology company partnership.
• Brickell Biotech, Inc.minorStrategic or Co-development PartnerCompleted kilogram-scale process development for BBI-4000 (novel topical soft-anticholinergic for hyperhidrosis).
• Cato Research (Allucent)minorStrategic or Co-development PartnerContract research organization partnership.
• Cerenis Therapeutics Holding SA (CEREN.PA)minorStrategic or Co-development PartnerInternational pharmaceutical company with multiple synthesis projects.
• IIT Research Institute (IITRI)minorStrategic or Co-development PartnerResearch institute collaboration.
• MLM Biologics, Inc.minorStrategic or Co-development PartnerBiologics company partnership.
• Mountain Valley MD Holdings Inc. (MVMD.CN)minorStrategic or Co-development PartnerPharmaceutical company partnership.
• MRIGlobalminorStrategic or Co-development PartnerResearch organization partnership for pharmaceutical development.
• Nanopharmaceutics, Inc.minorStrategic or Co-development PartnerRelated entity under shared President James D. Talton. Co-located at Alachua facility.
• Northwell HealthminorStrategic or Co-development PartnerHealthcare system partnership for clinical research.
• OPTOSURGICAL, LLCminorStrategic or Co-development PartnerSurgical technology company partnership.
• Oragenics, Inc. (NYSE: OGEN)minorStrategic or Co-development PartnerPharmaceutical company partnership.
• Praxis Bioresearch, LLCminorStrategic or Co-development PartnerBioresearch company partnership.
• Southern ResearchminorStrategic or Co-development PartnerResearch institute partnership for pharmaceutical development.
• Stanford UniversityminorStrategic or Co-development PartnerAcademic collaboration with Stanford University.
• TRACON Pharmaceuticals, Inc. (Nasdaq: TCON)minorStrategic or Co-development PartnerPharmaceutical company partnership.
• Univar Solutions Inc. (NYSE: UNVR)minorChannel Partner/ Reseller/ DistributorChemical distribution partnership.
• UF Innovate / Sid Martin BiotechminorStrategic or Co-development PartnerAcademic technology transfer and incubator partnership with University of Florida's biotech incubator.
• X-tosis, Inc.minorStrategic or Co-development PartnerPharmaceutical/biotech company partnership.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hovione: Portugal-headquartered CDMO specializing in custom synthesis, process development, and cGMP API manufacturing for small molecules. Closely comparable to Alchem in technical scope (small-molecule API process development through commercial manufacturing), niche size, and customer mix (pharma + government-sponsored programs).
• Sterling Pharma Solutions: UK-based CDMO providing custom synthesis, API process development, and cGMP manufacturing for small molecules. Comparable to Alchem in integrated service offering, scale, and focus on small-molecule API manufacturing for clinical and commercial supply.
• PCI Synthesis: U.S.-based custom synthesis and API manufacturing CRO with cGMP capabilities, comparable to Alchem in custom organic synthesis focus, mid-market scale, and pharma/biotech customer base.
• Regis Technologies: U.S. small-molecule custom synthesis and cGMP manufacturer offering process development, scale-up, and analytical services. Closely aligns with Alchem's custom synthesis and small-molecule API development offering.

Broad incumbents

• Cambrex: Larger U.S.-headquartered small-molecule API CDMO (private, owned by Permira) with broad cGMP capacity. Overlaps with Alchem on small-molecule API development and manufacturing but at a materially larger commercial scale and a wider portfolio.
• Curia (formerly AMRI): Global CRO/CDMO offering small-molecule API process development, cGMP manufacturing, and discovery services. Comparable to Alchem in end-to-end service model but at a much larger scale and broader geographic footprint.
• Piramal Pharma Solutions: Global CDMO providing small-molecule API process development and commercial cGMP manufacturing, including a meaningful U.S. onshoring footprint (Lexington, KY). Comparable to Alchem in the APIs it competes for, though at substantially greater scale and global reach.
• WuXi AppTec: Large global CRO/CDMO with extensive small-molecule API process development and manufacturing capabilities. A meaningful competitor to Alchem in commercial small-molecule CRO/CDMO bidding, differentiated by vast scale and a primarily offshore footprint.

Emerging players

• Sai Life Sciences: India-headquartered CRO/CDMO scaling small-molecule API process development and cGMP manufacturing. Comparable in service offering (custom synthesis through cGMP) and customer base (Western pharma/biotech) but pursuing international scale-up.

Others

• Eurofins Discovery: Eurofins is a strategic partner of Alchem (per the partnerships list) and provides adjacent analytical testing and laboratory services. Included as a comparable 'broad laboratory/advisory' counterpart for Alchem's analytical and CMC services rather than as a direct manufacturing competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alchem-laboratories-corp

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alchem Laboratories